Leerink Partners: Upgraded the Tandem Diabetes Care (TNDM.US) rating from the market unanimously to superior to the market rating, and the target price was adjusted from $34.00 to $45.00.
Leerink Partners：上调Tandem Diabetes Care(TNDM.US)评级，由大市一致调整至优于大市评级, 目标价由34.00美元调整至45.00美元。
Leerink Partners: Upgraded the Tandem Diabetes Care (TNDM.US) rating from the market unanimously to superior to the market rating, and the target price was adjusted from $34.00 to $45.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.